Live Breaking News & Updates on Merck Co Stock

Stay updated with breaking news from Merck co stock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA (pembrolizumab) Plus LYNPARZA (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility

07.12.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, for . ....

United States , Merck Research Laboratories , Merck Co Stock , Statement Of Merck Co Inc , Exchange Commission , Merck Co Inc , Merck Research , Response Evaluation Criteria , Solid Tumors , Induction Phase , Maintenance Phase , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse , Which Can Present With Diabetic , Nervous System , Patients With Multiple , Neck Squamous Cell , Mismatch Repair Deficient , Mismatch Repair Deficient Colorectal , Prescribing Information , Medication Guide , Acute Myeloid Leukemia , Fetal Toxicity , First Line Maintenance , Advanced Ovarian ,

Merck Helps To Improve Diversity in Clinical Trials Through Beacon of Hope

03.10.2023 - NORTHAMPTON, MA / ACCESSWIRE / October 3, 2023 / Merck & Co., Inc.Unique collaboration expands our clinical trials efforts to four Historically Black Medical School Clinical Trial Centers of ExcellenceIncreasing diversity in clinical trials plays a . ....

Adrelia Allen , Andy Lee , Morehouse School Of Medicine , Howard University College Of Medicine , Charlesr Drew University Of Medicine , School Clinical Trial Centers Of Excellence , Merck Co Stock , Merck Co Inc , Meharry Medical College , Morehouse School , Howard University College , Black Colleges , Merck Co Chart , Erck Co Kurs , Erck Co Aktie ,

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

25.05.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced data from the final pre-specified overall survival (OS) analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial investigating KEYTRUDA, . ....

United States , New Zealand , Gregory Lubiniecki , Corina Dutcus , Thomas Hutson , Global Clinical Development , International Metastatic , Eisai Co Ltd , Urologic Cancer Research , Database Consortium , Merck Research Laboratories , Eisai Europe Ltd , Treatment Center , Merck Co Inc , Urologic Oncology Program , Statement Of Merck Co Inc , Clinical Development , United Nations Sustainable Development Goals Sdgs , Eisai Inc , Texas Oncology At Baylor Sammons Cancer Center , Exchange Commission , Memorial Sloan Kettering Cancer Center , Oncology At Eisai Inc , Merck Co Stock , Texas Oncology , Baylor Sammons Cancer ,

Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)

07.04.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple . ....

United States , New Zealand , Gregory Lubiniecki , Corina Dutcus , Exchange Commission , Merck Co Stock , Data Monitoring Committee , Merck Co Inc , Eisai Co Ltd , Merck Research Laboratories , Oncology At Eisai Inc , Eisai Europe Ltd , Statement Of Merck Co Inc , Clinical Development , United Nations Sustainable Development Goals Sdgs , Global Clinical Development , Eisai Inc , Vice President , Merck Research , Senior Vice President , Response Evaluation Criteria , Solid Tumors , Mismatch Repair Deficient Colorectal , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse ,

Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference

21.11.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr. Eliav Barr, senior vice president and head of Global Clinical Development, chief medical officer, Merck Research Laboratories, is scheduled to participate . ....

United States , Statement Of Merck Co Inc , Exchange Commission , Merck Co Inc , Merck Co Stock , Looking Statement , Litigation Reform Act , Annual Report , Merck Amp Co ,